Jia xiang Jin, Varun R. Ginde, Stefanie Huhn, Philipp Reichert, Uta Bertsch, Roland Fenk, Britta Besemer, Amelie Boquoi, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Lisa B. Leypoldt, Bernhard Heilmeier, Christof Scheid, Thorsten Peters-Regehr, Igor W. Blau, Carsten Müller-Tidow, Steffen Luntz, Tobias A.W. Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Müller, Evgenii Shumilov, Wolfgang Knauf, Christian S. Michel, Thomas Geer, Hendrik Riesenberg, Christoph Lutz, Marc S. Raab, Niels Weinhold, Martin Hoffmann, Axel Benner, Peter Findeisen, Katja C. Weisel, Hans J. Salwender, Elias K. Mai, Hartmut Goldschmidt. "Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial." Journal of Clinical Oncology, 2026. doi:10.1200/jco-26-01346